Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
7.10
-0.04 (-0.56%)
At close: Sep 4, 2026, 4:00 PM EDT
7.07
-0.03 (-0.42%)
After-hours: Sep 4, 2026, 7:58 PM EDT
Precigen Revenue
Precigen had revenue of $54.98M in the quarter ending June 30, 2026, with 6,322.66% growth. This brings the company's revenue in the last twelve months to $85.72M, up 1,875.05% year-over-year. In the year 2025, Precigen had annual revenue of $9.68M with 146.73% growth.
Revenue (ttm)
$85.72M
Revenue Growth
+1,875.05%
P/S Ratio
29.66
Revenue / Employee
$535,731
Employees
160
Market Cap
2.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | 5.76M | 146.73% |
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Harmony Biosciences Holdings | 959.90M |
| Nuvation Bio | 169.90M |
| Viridian Therapeutics | 71.13M |
| Nektar Therapeutics | 54.59M |
| Nurix Therapeutics | 36.77M |
PGEN News
- 13 days ago - Precigen Q2 marked commercial inflection - TheFly
- 13 days ago - Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Accesswire
- 4 weeks ago - Precigen price target raised to $18 from $14 at H.C. Wainwright - TheFly
- 4 weeks ago - Precigen Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Precigen Earnings release: Q2 2026 - Filings
- 4 weeks ago - Precigen Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Precigen reports Q2 EPS 5c vs., (9c) last year - TheFly
- 4 weeks ago - Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth - PRNewsWire